Behavioral Change and Weight Management-Weight Management Treatment Options Infographic

Weight Management Treatment Options Infographic

Pdf Summary

This document provides guidelines for weight management treatment options for individuals with type 2 diabetes. The recommendations are based on the American Diabetes Association's (ADA) Standards of Care in Diabetes for 2023.<br /><br />The document highlights the importance of behavioral strategies to support diabetes self-management and engagement in health behaviors for optimal diabetes outcomes. It suggests that people with diabetes should be counseled on setting SMART goals, which are specific, measurable, actionable, timely, and realistic.<br /><br />The document also provides information on various pharmacological agents that can be used for weight management. It lists common side effects and possible safety concerns for medications such as phentermine, phentermine/topiramate ER, naltrexone/bupropion ER, liraglutide, and semaglutide. It also includes black box warnings for certain medications, indicating specific risks and precautions.<br /><br />Additionally, the document mentions short-term and long-term treatment options for weight management, including sympathomimetic amine anorectic, sympathomimetic amine anorectic/antiepileptic combination, opioid antagonist/antidepressant combination, and glucagon-like peptide 1 receptor agonist.<br /><br />The importance of "SMART" lifestyle modifications and a person-centered approach is emphasized as well. It suggests that individuals should work towards making sustainable changes to their lifestyle that are tailored to their specific needs and preferences.<br /><br />Finally, the document mentions orlistat, a lipase inhibitor, as an anti-obesity medication option.<br /><br />For more detailed information on approved obesity pharmacotherapy options, the document suggests referring to Section 8 of the ADA's Standards of Care in Diabetes for 2023.

Keywords

weight management treatment options

type 2 diabetes

American Diabetes Association

behavioral strategies

SMART goals

pharmacological agents

side effects

black box warnings

lifestyle modifications

orlistat